- Acute Heart Failure
- Advanced Heart Failure
- Case Studies
-
Symposia
-
ESC Heart Failure 2017 and the 4th World Congress on Acute Heart Failure
ESC Heart Failure 2017 and the 4th World Congress on Acute Heart Failure
- Inotropes in acute heart failure: How to apply guidelines in clinical practice
- Inotropes or inodilators in HFrEF: What to use, when and how?
- Repetitive use of inodilators in AdHF: The clinical practice in AdHF
- How to select clinical endpoints: Composite endpoints still clinically relevant?
- Inotropes and clinical trials: How to set relevant clinical endpoints?
- Inotropes in Acute Heart Failure: From guidelines to practical use
- Repetitive use of inodilators in AdHF: The scientific evidence in literature
- Proper treatment to avoid kidney dysfunction
- Inotropes in acute heart failure: Therapeutic needs vs available options
- Repetitive use of inodilators in advanced heart failure – The rationale
- Repetitive use of inodilators in advanced heart failure – The scientific evidence
- Repetitive use of inodilators in advanced heart failure – The clinical practice
- Inotropes or inodilators in Heart Failure with reduced Ejection Fraction (HFrEF): what to use, on whom, when and how? What is available
- Inotropes or inodilators in Heart Failure with reduced Ejection Fraction (HFrEF): what to use, on whom, when and how? The therapeutic needs
- Inotropes or inodilators in Heart Failure with reduced Ejection Fraction (HFrEF): what to use, on whom, when and how? The clinical practice
- Inodilators and renal function: how to avoid kidney dysfunction in Acute Heart Failure (AHF) – Cardiorenal syndrome
- Inodilators and renal function: how to avoid kidney dysfunction in Acute Heart Failure (AHF) – Therapeutic options: what, when and why
- Inodilators and renal function: how to avoid kidney dysfunction in Acute Heart Failure (AHF)
- Inotropes in acute heart failure: from guidelines to practical use – The ESC Guidelines in practice
- Inotropes in acute heart failure: from guidelines to practical use – Patients in need of inotropes
-
37th International Symposium on Intensive Care and Emergency Medicine
37th International Symposium on Intensive Care and Emergency Medicine
-
ESC Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure
ESC Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure
- Why and how to treat patients in cardiogenic shock with inodilators
- Why and how to use inodilators in intermittent dose on patients with advanced heart failure
- How to treat patients during deterioration of heart failure to avoid kidney dysfunction: Pharmacological options
- Why and how to use inodilators as a bridge to transplant or assist device
- Why and how to treat advanced heart failure patients with repetitive doses of inodilator
-
31st Annual Congress of the European Association of Cardiothoracic Anaesthesiology
31st Annual Congress of the European Association of Cardiothoracic Anaesthesiology
-
35th International Symposium on Intensive Care and Emergency Medicine
35th International Symposium on Intensive Care and Emergency Medicine
-
34th International Symposium on Intensive Care and Emergency Medicine
34th International Symposium on Intensive Care and Emergency Medicine
-
24th Annual Congress of the European Society of Intensive Care Medicine
24th Annual Congress of the European Society of Intensive Care Medicine
-
38th International Symposium on Intensive Care and Emergency Medicine
38th International Symposium on Intensive Care and Emergency Medicine
- Efficacy and safety of levosimendan in the light of clinical practice
- The haemodynamic effects of levosimendan: which patient will benefit from them?
- Is the prolonged action of levosimendan of relevance with our patient length of stay and pathologies?
- Perioperative effects of levosimendan in CABG
- Renal effects of levosimendan
-
European Society of Cardiology - Heart Failure 2018
European Society of Cardiology - Heart Failure 2018
- Cardio-renal syndrome - Levosimendan and renal function: how to avoid kidney dysfunction in AHF?
- Therapeutic options - Levosimendan and renal function: how to avoid kidney dysfunction in AHF?
- Clinical practice - Levosimendan and renal function: how to avoid kidney dysfunction in AHF?
- What is available? - Levosimendan in HFrEF: what to use, on whom, when and how?
- Therapeutic needs - Levosimendan in HFrEF: what to use, on whom, when and how?
- Clinical practice - Levosimendan in HFrEF: what to use, on whom, when and how?
- Scientific evidence in the literature - Repetitive use of levosimendan in advanced heart failure
- Patient characteristics - Repetitive use of levosimendan in advanced heart failure
- Clinical practice and new data - Repetitive use of levosimendan in advanced heart failure
- Patient characteristics - Inotropes in acute heart failure: from guidelines to practical use
- Clinical practice and therapeutic options - Inotropes in acute heart failure: from guidelines to practical use
-
ESC Heart Failure 2017 and the 4th World Congress on Acute Heart Failure
- Featured Publications
-
Resources
-
Expert Opinions
Expert Opinions
- Levosimendan roars ahead as LION-HEART results published
- Acute and Advanced Heart Failure: new data, new studies, new opinions, new trends
- FIGHT, PERSIST and LEVOREP
- Heart failure and rehospitalisation
- LION-Heart and LAICA clinical trials: differences and similarities
- ESC 2017 in Barcelona
- What could be worse than heart failure?
- Acute heart failure and renal function: an organ interplay not to be underestimated
- Hospitalisation for the management of acute decompensation
- LEODOR trial - recent advances
- What does the Advanced Heart Failure patient want?
- Levosimendan in Cardiac Surgery: The Evidence Adds Up
- Another Uptick for Levosimendan in Advanced Heart Failure
- European Society of Cardiology 2018
-
Expert Opinions
- Events
- Language English
The levosimendan lectures (Orion-sponsored events)
Listed here are 3 videos from Zoltàn Papp, Per Kivdal and John Parissis detailing the efficacy of levosimendan for the management of heart failure.
-
The mechanism of action of levosimendan: a cardioprotective inodilator
Zoltàn Papp discusses the cardioprotective mechanism of action of levosimendan as an inodilator.
-
Repetitive treatment with levosimendan in practice
Per Kvidal discusses the use of repetitive or long-term levosimendan treatment.
-
Levosimendan for the management of patients with acute cardiorenal syndrome
John Parissis discusses the use of levosimendan in patients with acute cardiorenal syndrome.
Alternatively login via
Related Learning Zones
Cardiovascular Metabolism Knowledge Centre
Pain, Agitation and Delirium (PAD) Management
Chronic Obstructive Pulmonary Disease (COPD)
Back to epgonline.org